Lina Yin

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Thomas Powles, Elizabeth R. Plimack, Denis Soulières et al. · The Lancet Oncology · 2020 · 745 citations

Medicine, Oncology, Pharmacology +13

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.

Elizabeth R. Plimack, Brian I. Rini, V.P. Stus et al. · Journal of Clinical Oncology · 2020 · 65 citations

Medicine, Oncology, Pharmacology +11

The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix

Xuan Pei, Libing Xiang, Wei Chen et al. · Gynecologic Oncology · 2021 · 45 citations · Full text

Medicine, Genetics, Oncology +15

Ovarian transposition before radiotherapy in cervical cancer patients: functional outcome and the adequate dose constraint

Lina Yin, Saiquan Lu, Jun Zhu et al. · Radiation Oncology · 2019 · 40 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Synergistic anti-oxidant and anti-inflammatory effects of ceria/resatorvid co-decorated nanoparticles for acute lung injury therapy

Yue Wu, Yawen Zhang, Xuanyu Tang et al. · Journal of Nanobiotechnology · 2023 · 33 citations · Full text

Medicine, Pharmaceutics, Pharmacology +17